To improve outcomes for patients hospitalized with COVID-19, researchers led by Mitchell Lazar of the Perelman School of Medicine are exploring which populations are most prone to side effects when treated with glucocorticoids, a type of steroid.

July 28, 2021 ・ From WHYY (Philadelphia)